Newsroom
Strive to Deliver Breakthroughs
-
July 20, 2021
Harbour BioMed Appoints Yingying Chen, PhD, as Chief Financial Officer
Cambridge, MA, Rotterdam, NL, Suzhou, CN – July 20, 2021 Harbour BioMed (“HBM”, HKEX:02142) announced the appointment of Dr. Yin...
View more -
July 16, 2021
Harbour BioMed Announces Last Patient Dosing of Phase1b/2a Study of Anti-FcRn Batoclimab for Treating Neuromyelitis Optica Spectrum Disorder
Cambridge, MA, Rotterdam, NL, Suzhou, CN— July 16, 2021 Harbour BioMed (“HBM”, HKEX: 02142) today announced ...
View more -
July 06, 2021
Harbour BioMed Reports Positive Topline Results from Phase 2 Trial of Batoclimab (HBM9161) in Generalized Myasthenia Gravis
Cambridge, MA, Rotterdam, NL, Suzhou, CN— July 6, 2021 Both batoclimab 340 mg and 680 mg treatment groups demonstrated rapid, subst...
View more -
June 22, 2021
Harbour BioMed Appoints Amy Que, PhD, as Chief Technology Officer
Harbour BioMed (HBM) announced the appointment of Dr. Amy Que as Chief Technology Officer (CTO). Dr. Que will lead the Chemistry, Manufacture and Con...
View more -
June 17, 2021
Harbour BioMed Announces Dosing of First Patient of Next-Generation Anti-CTLA-4 Antibody in Combination with PD-1 Antibody in Patients with NSCLC
Cambridge, MA, Rotterdam, NL, Suzhou, CN – June 17, 2021 Harbour BioMed (“HBM”, HKEX: 02142) today announced the dosing of the f...
View more -
June 16, 2021
Harbour BioMed and Dana-Farber Cancer Institute Collaborate to Advance Novel Biotherapies for Cancer Treatment
Cambridge, MA, Rotterdam, NL, Suzhou CN – June 16, 2021 Harbour BioMed (HKEX: 02142) announced today it has entered into a multi-y...
View more -
June 08, 2021
HabourBioMed will announce a bispecific antibody at Antibody Engineering & Therapeutics Conference
HabourBioMed will announce a bispecific antibody at Antibody Engineering & Therapeutics （AET）Conference (June 8-10, 2021). This anti...
View more -
June 02, 2021
Capital Group increased its stake in Harbour BioMed to 6.1%
CAMBRIDGE, Mass., SUZHOU, China and ROTTERDAM, Netherlands - June 2, 2021 According to public information, on May 31, the C...
View more -
May 11, 2021
Harbour BioMed Announces Dosing of First Patient in Phase Ib/IIa Clinical Study of its Next-Generation Anti-CTLA-4 Antibody
CAMBRIDGE, Mass., SUZHOU, China and ROTTERDAM, Netherlands - May 11, 2021 Harbour BioMed (“HBM”, HKEX: ...
View more -
April 13, 2021
Harbour BioMed Presents Novel Antibody for Cancer Immunotherapy at 2021 American Association for Cancer Research Annual Meeting
CAMBRIDGE, Mass., SUZHOU, China and ROTTERDAM, Netherlands - April 13, 2021 Harbour BioMed ("HBM"; ...
View more
Copyright © 2025 Harbour BioMed. All Rights Reserved
沪公网安备31011502401396号
沪ICP备19015946号-1